跳至主要内容
临床试验/NCT02244047
NCT02244047已完成1 期

Exploratory, Placebo-controlled Study on the Effects of Bifidobacterium Breve in Children With Celiac Disease

University Medical Centre Maribor0 个研究点目标入组 66 人开始时间: 2013年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
66
主要终点
Serum TNF-alpha decrease after Bifidobacterium breve daily consumption in children with celiac disease

研究概览

简要总结

Celiac disease (CD) is an immune-mediated systemic disease that is elicited by consumption of gluten and related prolamines in genetically susceptible individuals. Not only genetic but also environmental factors play an important role in CD pathogenesis. CD patients have imbalance in the gut microbiota, they have reduced number of Bididobacterium species in feces and biopsies.

Up till now, only effective treatment for CD is life long adherence to gluten free diet. If gluten free diet is not strict that leads over the years to complications of disease, such as autoimmune diseases, psychiatric diseases, osteoporosis etc. That may be caused by continuous recirculation of activated immune cells between the inflamed organ and the periphery. To avoid complications of disease in long term the investigators want to test specific probiotic bacteria from Bifidobacteria genus, that has has been in vitro studies recognized as anti-inflammatory.

Hypothesis

  1. Children with celiac disease on gluten free diet have a higher level of pro-inflammatory cytokine (TNF-alpha) and anti-inflammatory cytokine (IL-10) in comparison with healthy controls.
  2. 3 months after daily probiotic consumption TNF-alpha level decrease and IL-10 level increase.

In the investigators research will be selected 70 children, age from 2 to 18 years, divided in different groups:

  1. Group: 25 children with celiac disease on GFD for at least 3 months and will receive probiotic for 3 months.
  2. Group: 25 children with celiac disease on GFD for at least 3 months and will receive placebo for 3 months.
  3. Group: 20 healthy children

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Single (Participant)

入排标准

年龄范围
1 Year 至 18 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • celiac disease on gluten free diet

排除标准

  • acute or chronic diseases,
  • permanent use of medication and
  • ingestion of antibiotics at least one month prior to study

研究组 & 干预措施

Bifidobacterium breve

Active Comparator

Bifidobacterium breve BR03 and B632 powder containing 10/9 CFU daily dosage in a period of 3 months

干预措施: Bifidobacterium breve (Drug)

Placebo

Active Comparator

Placebo in the same powder packages as Bifidobacterium breve

干预措施: Placebo (for Bifidobacterium breve) (Drug)

结局指标

主要结局

Serum TNF-alpha decrease after Bifidobacterium breve daily consumption in children with celiac disease

时间窗: 3 months

次要结局

未报告次要终点

研究者

发起方
University Medical Centre Maribor
申办方类型
Other
责任方
Principal Investigator
主要研究者

Martina Klemenak

medical doctor, resident at Pediatric department

University Medical Centre Maribor

相似试验